Alan Krieger, MD
Urology · Rahway, NJNPI 1740385772
Payments from drug & device makers
Across 90 payments — averaging $36.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$749
- Urogen Pharma, Inc.$239
- AbbVie$213
- Bayer$194
- Pfizer$179
- Endo Pharmaceuticals Inc.$147
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,18498%
- Education$662%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 13 | $749 |
| Urogen Pharma, Inc. | 2 | $239 |
| AbbVie(2 entities) | 15 | $213 |
| Bayer | 5 | $194 |
| Pfizer | 5 | $179 |
| Endo Pharmaceuticals Inc. | 4 | $147 |
| Axonics, Inc. | 1 | $130 |
| Ferring Pharmaceuticals Inc. | 3 | $129 |
| Progenics Pharmaceuticals, Inc. | 1 | $125 |
| Blue Earth Diagnostics | 3 | $124 |
| AstraZeneca | 1 | $122 |
| Procept Biorobotics Corporation | 2 | $115 |
| Teleflex LLC | 4 | $114 |
| SRS Medical Systems, Inc. | 1 | $104 |
| Neotract Inc. | 4 | $87 |
| Astellas Pharma US Inc | 2 | $66 |
| Johnson & Johnson(2 entities) | 4 | $64 |
| 180 Medical, Inc. | 2 | $49 |
| Amgen | 3 | $43 |
| Dendreon Pharmaceuticals LLC | 2 | $37 |
| Medtronic | 1 | $33 |
| EMD Serono, Inc. | 2 | $29 |
| Aytu Biopharma, Inc. | 2 | $28 |
| Olympus America Inc. | 1 | $22 |
| Hollister Incorporated | 1 | $19 |
| Rochester Medical Corporation | 1 | $17 |
| Metuchen Pharmaceuticals | 1 | $15 |
| Merck | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
| Dentsply IH Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JELMYTO$239
- GREENLIGHT$186
- Bulkamid$130
- Axonics$130
- GENERAL KIDNEY STONE DISEASE$129
- XTANDI$125
- PYLARIFY$125
- GENERAL ERECTILE DYSFUNCTION$122
- Nubeqa$117
- XIAFLEX$106
- ADSTILADRIN$104
- Spanner Prothetic Stent$104
How this compares
$3,249 in reported general payments places this provider in the 55th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 23 | $28,090 |
| GemtesaVibegron | 17 | $17,948 |
| Tamsulosin Hcl | 687 | $12,907 |
| Finasteride | 326 | $5,394 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 75 | $3,071 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 20 | $3,071 |
| Dutasteride | 48 | $2,261 |
| Potassium Citrate ErPotassium Citrate | 14 | $1,591 |
| Methenamine Hippurate | 14 | $1,285 |
| Tolterodine Tartrate ErTolterodine Tartrate | 14 | $1,058 |
| Silodosin | 12 | $981 |
| Oxybutynin Chloride ErOxybutynin Chloride | 25 | $937 |
| Oxybutynin Chloride | 55 | $742 |
| Cephalexin | 48 | $583 |
| CefuroximeCefuroxime Axetil | 15 | $427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $66 | $28,09023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 401 urology providers in New Jersey.
Other urology in Rahway
- Domenico SavattaRahway$23K
- Gordon BrownCherry Hill$2.8M
- Nitin YerramHackensack$1.6M
- Michael StifelmanHackensack$1.5M
- Thomas MuellerLinwood$1.2M
- David SussmanLinwood$833K
- Michael IngberDenville$607K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$464K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.